TuHURA Biosciences Inc
HURA0.819USD
-0.068-7.69%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
41.96MMarket Cap
0.10P/E TTM
More Details of TuHURA Biosciences Inc Company
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
TuHURA Biosciences Inc Info
Ticker SymbolHURA
Company nameTuHURA Biosciences Inc
IPO dateJul 12, 2016
CEOBianco (James)
Number of employees19
Security typeOrdinary Share
Fiscal year-endJul 12
Address10500 University Center Dr.
CityTAMPA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33612
Phone18138756600
Websitehttps://tuhurabio.com/
Ticker SymbolHURA
IPO dateJul 12, 2016
CEOBianco (James)
Company Executives of TuHURA Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
1.88K
--
Mr. George Ng
Mr. George Ng
Independent Director
Independent Director
--
--
Dr. Craig Tendler, M.D.
Dr. Craig Tendler, M.D.
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Dr. James S. Manuso, Ph.D.
Dr. James S. Manuso, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. James Bianco, M.D.
Dr. James Bianco, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Dan Dearborn, CPA
Mr. Dan Dearborn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan List, M.D.
Dr. Alan List, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
1.88K
--
Mr. George Ng
Mr. George Ng
Independent Director
Independent Director
--
--
Dr. Craig Tendler, M.D.
Dr. Craig Tendler, M.D.
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Dr. James S. Manuso, Ph.D.
Dr. James S. Manuso, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. James Bianco, M.D.
Dr. James Bianco, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Patel (Vijay)
13.17%
Patel (Samir Rashmikant)
4.56%
Bianco (James A)
3.83%
Nachtrab (Matthew)
3.81%
The Vanguard Group, Inc.
3.74%
Other
70.90%
Shareholders
Shareholders
Proportion
Patel (Vijay)
13.17%
Patel (Samir Rashmikant)
4.56%
Bianco (James A)
3.83%
Nachtrab (Matthew)
3.81%
The Vanguard Group, Inc.
3.74%
Other
70.90%
Shareholder Types
Shareholders
Proportion
Individual Investor
28.63%
Investment Advisor
7.43%
Investment Advisor/Hedge Fund
2.43%
Corporation
1.50%
Bank and Trust
0.13%
Research Firm
0.11%
Pension Fund
0.05%
Venture Capital
0.03%
Other
59.69%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
99
6.50M
12.73%
+2.07M
2025Q2
61
22.69M
48.75%
+618.64K
2025Q1
62
22.01M
50.38%
+1.51M
2024Q4
59
20.49M
48.45%
+20.45M
2024Q3
46
25.82K
1.63%
-5.58K
2024Q2
47
25.48K
1.61%
+5.54K
2024Q1
51
16.48K
5.54%
+3.94K
2023Q4
52
9.23K
7.03%
+1.15K
2023Q3
58
5.06K
11.22%
-4.59K
2023Q2
63
4.35K
10.03%
-4.29K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Patel (Vijay)
8.00M
15.65%
--
--
Sep 11, 2025
Patel (Samir Rashmikant)
2.77M
5.41%
+452.84K
+19.57%
Sep 11, 2025
Bianco (James A)
2.32M
4.55%
--
--
Sep 11, 2025
Nachtrab (Matthew)
2.31M
4.52%
+2.31M
--
Sep 11, 2025
The Vanguard Group, Inc.
2.23M
4.37%
+358.71K
+19.13%
Jun 30, 2025
Theofilos (Charles Steve)
1.98M
3.87%
--
--
Jul 31, 2025
BlackRock Institutional Trust Company, N.A.
1.22M
2.39%
+874.93K
+251.87%
Jun 30, 2025
Geode Capital Management, L.L.C.
582.99K
1.14%
+307.26K
+111.43%
Jun 30, 2025
KP Biotech Group LLC
447.23K
0.88%
-1.68M
-78.96%
Jun 12, 2025
CA Patel F&F Investments, LLC
447.23K
0.88%
-1.68M
-78.96%
Jun 12, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
Date
Type
Ratio
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Oct 04, 2024
Merger
35→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
Nov 11, 2022
Merger
50→1
FAQs
Who are the top five shareholders of TuHURA Biosciences Inc?
The top five shareholders of TuHURA Biosciences Inc are:
Patel (Vijay) holds 8.00M shares, accounting for 15.65% of the total shares.
Patel (Samir Rashmikant) holds 2.77M shares, accounting for 5.41% of the total shares.
Bianco (James A) holds 2.32M shares, accounting for 4.55% of the total shares.
Nachtrab (Matthew) holds 2.31M shares, accounting for 4.52% of the total shares.
The Vanguard Group, Inc. holds 2.23M shares, accounting for 4.37% of the total shares.
Patel (Vijay) holds 8.00M shares, accounting for 15.65% of the total shares.
Patel (Samir Rashmikant) holds 2.77M shares, accounting for 5.41% of the total shares.
Bianco (James A) holds 2.32M shares, accounting for 4.55% of the total shares.
Nachtrab (Matthew) holds 2.31M shares, accounting for 4.52% of the total shares.
The Vanguard Group, Inc. holds 2.23M shares, accounting for 4.37% of the total shares.
What are the top three shareholder types of TuHURA Biosciences Inc?
The top three shareholder types of TuHURA Biosciences Inc are:
Patel (Vijay)
Patel (Samir Rashmikant)
Bianco (James A)
Patel (Vijay)
Patel (Samir Rashmikant)
Bianco (James A)
How many institutions hold shares of TuHURA Biosciences Inc (HURA)?
As of 2025Q3, 99 institutions hold shares of TuHURA Biosciences Inc, with a combined market value of approximately 6.50M, accounting for 12.73% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -36.02%.
What is the biggest source of revenue for TuHURA Biosciences Inc?
In --, the -- business generated the highest revenue for TuHURA Biosciences Inc, amounting to -- and accounting for --% of total revenue.
